Area of research
Epidemiology · Hepatology
Research interest
Research focused on Entecavir and HBsAg, with related work in Placebo, Gastroenterology, Double blind. Notable publications include 'Transcriptional Co-activator p300 Maintains Basal Hepatic Gluconeogenesis', 'Combination of entecavir with thymosin alpha-1 in HBV-related compensated cirrhosis: a prospective multicenter randomized open-label study', and 'On‐treatment changes of liver stiffness at week 26 could predict 2‐year clinical outcomes in HBV ‐related compensated cirrhosis'.
Single-dose suraxavir marboxil for acute uncomplicated influenza in adults and adolescents: a multicenter, randomized, double-blind, placebo-controlled phase 3 trial
Author Correction: Single-dose suraxavir marboxil for acute uncomplicated influenza in adults and adolescents: a multicenter, randomized, double-blind, placebo-controlled phase 3 trial
Lower end of treatment HBsAg and HBcrAg were associated with HBsAg loss after nucleos(t)ide analog cessation
IP10 and Anti-HBc can Predict Virological Relapse and HBsAg Loss in Chronic Hepatitis B Patients after Nucleos(t)ide Analog Discontinuation
HBsAg ≤ 135 IU/mL or HBcrAg ≤ 3.6 logU/mL was associated with HBsAg loss after nucleos(t)ide analogue cessation
Hydronidone for the Treatment of Liver Fibrosis Related to Chronic Hepatitis B: A Phase 2 Randomized Controlled Trial
HBeAg-positive patients with HBsAg < 135IU/ml or HBcrAg < 3.6logU/ml have more chance to be HBsAg loss after nucleos (t)ide analogue cessation
HBeAg-positive patients with HBsAg < 100 IU/mL and negative HBV RNA have lower risk of virological relapse after nucleos(t)ide analogues cessation
Efficacy of a combination of HBV RNA and HBeAg in predicting HBeAg seroconversion in patients treated with entecavir for 144 weeks
Combination of entecavir with thymosin alpha-1 in HBV-related compensated cirrhosis: a prospective multicenter randomized open-label study
On‐treatment changes of liver stiffness at week 26 could predict 2‐year clinical outcomes in <scp>HBV</scp>‐related compensated cirrhosis
Transcriptional Co-activator p300 Maintains Basal Hepatic Gluconeogenesis